<DOC>
	<DOCNO>NCT00998920</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability escalate multiple dos S-equol administer twice daily ( BID ) 14 day healthy male female subject describe pharmacokinetic profile S-equol .</brief_summary>
	<brief_title>Multi-Dose Safety Pharmacokinetic Study S-Equol Healthy Volunteers</brief_title>
	<detailed_description>The study randomize , double-blind , placebo-controlled trial dos escalate cohort . Volunteers randomize receive active study drug placebo twice daily ( BID ) 14 day . This study stagger time single rise dose study ( Protocol AUS-CT01 ) conduct concurrently , low dose cohort multiple rise dose study may begin evaluation safety pharmacokinetic data first 8 subject randomize 10 mg dose cohort single rise dose study safety data 8 Subjects randomize 20 mg dose cohort study .</detailed_description>
	<mesh_term>Equol</mesh_term>
	<criteria>subject capable reading , understand comply protocol sign informed consent document prior undergo study related procedure ; subject male female 18 ( time consent ) 65 year age , inclusive ( subject require meet latter age limit time first dose ) ; subject , female , must nonlactating , negative serum pregnancy test result Pretreatment Period . Women childbearing potential must willing stay clinic Day 10 end dosing period confirm nonpregnant status . subject , female , must surgically sterile ( must document ) ; postmenopausal ( define least 2 year without menses screen FSH expect range ) must use acceptable method nonhormonal contraception ( Mirena acceptable ) . For study , estrogencontaining contraceptive acceptable . Postmenopausal woman must vaginal spot bleed past year ; subject hormonal agent device within 4 week prior enrollment ( Mirena acceptable . n.b . Mirena cause irregular menstrual cycle ; however , would exclusionary purpose protocol ) ; subject , woman childbearing potential , must two consecutive normal menstrual cycle immediately prior enrollment ; subject must good health determine physician ( i.e. , via medical history Pretreatment Screening Period , physical examination screen laboratory result Pretreatment Screening Baseline Periods ) ; subject must weigh least 50 kg Body Mass Index ( BMI ) 18 30 , inclusive , Pretreatment Screening Period ; subject must normal clinical laboratory test result , abnormal , clinical laboratory test clinically significant Investigator 's opinion , Pretreatment Periods ; subject must negative drug alcohol toxicology screen Pretreatment Screening Period ; subject must negative HIV antibody hepatitis panel screen result Pretreatment Screening Period . For men 44 year age , Prostate Specific Antigen ( PSA ) less equal 2.0 ng/mL ; For woman 44 year age , mammography ( within 3 month prior Day 1 ) pelvic ultrasound , result show significant abnormality opinion Investigator , specifically suggestion breast endometrial neoplasm ; subject must Protein C Protein S activity level low limit normal ; subject must negative test Factor V Leiden . subject history chronic condition clinical significance , Investigator 's opinion , would preclude participation study ( e.g . clinically significant cardiovascular , hepatic , renal , gastrointestinal abnormality ) ; subject total bilirubin level great 0.9 mg/dL , conjugate bilirubin great 0.4 mg/dL unconjugated bilirubin great 0.8 mg/dL Screening ; Fasting cholesterol level screen great 280 mg/dL ; Fasting triglyceride level screen great 1.5 x upper limit normal ; subject history thromboembolic event estrogendependent benign malignant neoplasm ; subject rest systolic blood pressure &gt; 140 mm Hg &lt; 90 mm Hg , diastolic blood pressure &gt; 90 mm Hg &lt; 60 mm Hg Pretreatment Screening Period ; subject rest pulse &gt; 100 beats/minute &lt; 45 beats/minute Pretreatment Screening Period ; subject normal 12lead electrocardiogram ( ECG ) Pretreatment Screening Period , , abnormal , ECG clinically significant opinion Investigator ; subject unwilling comply study rule , include attempt void specify time ( prior ECG time point ) maintain quiet , undistracted , awake , motionless supine posture specify time point exhibit anxious , excitable , hostile , emotionally reactive affect ; subject tolerate control , quiet study conduct environment , include avoidance specify time point music , TV , movie , game activity may cause excitement , emotional tension arousal ; subject history sudden cardiac death immediate family , personal history cardiac disease , treat hypertension , congestive heart failure , unexplained syncope ; subject previous history cancer , basal cell carcinoma stage 1 squamous cell carcinoma successfully treat ; subject take prescription overthecounter medication within 1 week prior Pretreatment Baseline Period ( Day 1 ) , anticipate need medication course study ; subject history intolerance estrogen medication ; subject history substance abuse , drug addiction , alcoholism within 3 year prior Pretreatment Baseline Period . ( According DSM IV , alcohol abuse define average consumption 4 alcoholic drink per day . ) ; subject anticipate inability abstain alcohol , caffeine Yerba mate tea , grapefruit , grapefruit juice , flavonoidrich food 48 hour prior administration study medication throughout duration study . Coca tea mate de coca allow within 1 week prior Screening ; subject history smoking use tobacco product within 6 month prior Pretreatment Baseline Period ; subject donate blood blood product within 30 day prior Pretreatment Baseline Period ; subject mentally unstable incapable compliant protocol ; subject receive investigational test substance within 60 day prior administration investigational test article , anticipate receive investigational test substance Sequol course study ; subject previously enrol study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Healthy volunteer</keyword>
</DOC>